#American Institute for Cancer Research recommendations

[reading-writing-revolution]

Over the past week I’ve had two big takes: The clouds are darkening, and the opposition is assembling.

Trump’s first 90 days have been both chaotic and predictable. Shortly after Trump’s election, we predicted he would overreach by steamrolling through Project 2025. We warned that our only effective strategy to halt the slide into authoritarianism depends on unified opposition. We recommended people organize that opposition on the ground. Since then we’ve seen a wave of methodical grassroots organizing that has produced the fastest growth in new locally led Indivisible groups since we started Indivisible more than 8 years ago.

But that opposition movement in Congress was flat-footed, in the words of one US Representative. In response to this “roll over and play dead” strategy, Trump did not moderate or slow down. He empowered his top donor, Elon Musk, to ransack the federal government. Together they dismantled agencies and defunded programs for special needs students, cancer researchers, and disaster preparedness. They have menaced the press, the business community, the law firms, the universities, the courts, America’s closest international partners, and the American public itself. 

When the bullies found lax opposition, they escalated their bullying.

We are building a unified opposition. In the days after the inauguration this year, Representatives like Maxwell Frost, Jamie Raskin, and Jasmine Crockett joined us at a boisterous rally outside the DOGE-ransacked US Treasury building. Frost asked the crowd, “Are we the minority or are we the opposition?” Chris Murphy has consistently been on the front lines using every bullhorn he can find to shout “THIS IS AN EMERGENCY.” Cory Booker gave the longest speech in history of the US Senate to bring attention to the crisis. AOC and Bernie have drawn enormous crowds for their anti-Oligarchy tour in red and blue states.

Days ago, Sen. Chris Van Hollen flew to El Salvador to meet with a Maryland father of three who Trump had disappeared to a torture prison. Van Hollen lambasted California Governor Gavin Newsom for calling the camps a distraction, “anybody who can't stand up for the Constitution and the right of due process doesn't deserve to lead.” When House Republicans tried to prevent House Dems from making similar trips, the Dems told them to shove it. 

In a moment like this, leaders of institutions, leaders of communities, and leaders in elective office are all looking around to see which way the people are going. Faced with a set of ridiculous demands from Trump, Harvard University boldly, clearly, and defiantly said NO. We have heard from credible sources who were organizing at Harvard, that their oppositional stance was directly influenced by the massive, peaceful, April 5 Hands Off! protests around the world. We have heard from our friends on Capitol Hill that the rolling waves of mass protest and town halls and empty chair town halls are injecting some courage into the halls of Congress. Organized people power is turning the tide -- it’s not happening all at once, or as fast as we might like, but it’s happening.

Regardless of what they throw at us -- we will organize. We desperately need this unified opposition to take shape, because the clouds continue to darken. In response to Harvard’s defiance, Trump escalated his bullying -- threatening to take away the university’s tax status. Inside DC and across the country, rumors are swirling that Trump could be coming after political opponents in nonprofits in the coming days. The rumored executive orders may target climate groups on Earth Day (tomorrow), or perhaps more broadly seeking to neutralize any nonprofits that could be seen as a threat.

At Indivisible, we are tracking this closely and will be responding quickly when and if these escalations against civil society materialize. But regardless of what comes, I want to be clear: Indivisible will not back down from peacefully and aggressively organizing the opposition to these power-hungry, money-grubbing authoritarians. If something big goes down in the coming days -- we will be communicating over email, text, and on BlueSky: Find me, Leah, and Indivisible there. And come hell or high water you can find me and Leah on a weekly live Whats The Plan discussion at 3pm ET on Thursdays. 

Courage is contagious. Read on to Indivisible’s weekly action items to help spread it around.

-- Ezra Levin Co-Executive Director, Indivisible

[vinylspinning]

Frank Zappa: Broadway the Hard Way (1988)

If you think today's batshit crazy MAGA republicans are anything new, you weren't paying attention to Frank Zappa some 35 years ago, but it's never too late to catch up via this interview with Charlie Rose.

The P.M.R.C.'s moronic crusade against smut in pop music had reawakened Zappa's political activism to the point that he was putting almost as much time and energy into it as he was music music by the time his life was tragically cut short by cancer in 1993.

But Zappa never seemed to respect the public's intelligence (can you blame him?), so he spent much of his long career couching his intellectual insights and pointed criticism with flippant humor, dirty jokes, and satire so thick you could cut it with a knife.

This M.O. returned in full force on 1988's Broadway the Hard Way, which featured mostly new songs captured in concert (and then sometimes augmented in Frank's home studio, the Utility Muffin Research Kitchen) during what turned out to be Zappa's final world tour. (*)

Problem is, much of this music was incidental -- if impressively performed, as usual, by another cracking backing band (**) -- to the lyrics, so anyone seeking the improvisational, virtuosic Zappa concert experience had look elsewhere.

This LP was all about satirical put-downs, and Frank's targets included disgraced televangelists Jim and Tammy Bakker ("Jesus Thinks You're a Jerk"), conservative pundit Pat Robertson ("When the Lie's So Big"), perennial presidential candidate Jesse Jackson ("Rhymin' Man"), then-Surgeon General C. Everett Koop ("Promiscuous"), and even old favorite Richard Nixon ("Dickie's Such an Asshole"), because ... why not?

Zappa also name-checked several Reagan-era bad actors (Oliver North, Bill Casey, George Bush) and cultural touchstones (Wall Street greed, toxic upward mobility, super models!) in songs like "Planet of the Baritone Women," "Any Kind of Pain" (***), and "The Untouchables."

And that was just the vinyl release you see here, because as an early proponent of the compact disc, Zappa loaded up twice as many tunes into Broadway the Hard Way's CD version.

He also doubled the abuse, indicting both Reaganomics ("Hot Plate Heaven at the Green Hotel") and his hometown L.A. politics ("Jezebel Boy"), before skewering pop stars old and new on "Elvis Has Just Left the Building" and the Michael Jackson-lampooning "Why Don't You Like Me?" (****)

Another rock star of the day, Sting, joins Zappa and band on-stage to jam on The Police's "Murder by Numbers," which is reason enough to own the CD, as are a cover of Oliver Nelson's jazz standard "Stolen Moments" and a mournful rendition of Joe's Garage's "Outside Now."

All that being said, I would only recommend Broadway the Hard Way to dedicated Zappa fans (*****), even though another clueless American institution later nominated it for the 1990 'Best Musical Cast Show Album' Grammy, which went to Jerome Robbins' Broadway!

So can we really blame Zappa -- who, to his credit, set up voter registration booths wherever he could on those final tours -- for looking down his long nose at most of his fellow Americans?

Broadway the Hard Way, indeed.

* Said tour had come to a grinding halt in Genoa, Italy, amid a full-scale band mutiny, but with 81 shows already in the bag, Zappa had enough material with which to compile Broadway the Hard Way, the instrumentally focused Make a Jazz Noise Here, and the covers-laden The Best Band You Never Hard in Your Life LPs.

** Including the great Ike Willis, Bruce Fowler, Chad Wackerman, plus Robert Martin ("from Philadelphia, Curtis Institute graduate, 1971"), who showed off his operatic pipes on "Planet of the Baritone Women."

*** This track's first known instrumental performance dates all the way back to 1976 but words were only added for this release.

**** Built atop the same musical bed as 1970's "Tell Me You Love Me."

***** Other random song snippets peppered across the set include "Louie Louie," "Strawberry Fields Forever," "Rock of Ages," "Happy Days Are Here Again", "Hava Nagila", "La Cucaracha," "Frère Jacques," the "Battle Hymn of the Republic," and the Twilight Zone theme.

More Frank Zappa: Freak Out!, Absolutely Free, Lumpy Gravy, We’re Only in it for the Money, Cruising with Ruben and the Jets, Uncle Meat, Hot Rats, Burnt Weenie Sandwich, Weasels Ripped My Flesh, Chunga’s Revenge, Fillmore East – June 1971, 200 Motels,Just Another Band from L.A., Waka/Jawaka, The Grand Wazoo, Over-nite Sensation, Apostrophe (’), Roxy & Elsewhere, One Size Fits All, Bongo Fury, Zoot Allures, Studio Tan, Sleep Dirt, Sheik Yerbouti, Orchestral Favorites, Joe’s Garage Act I, Joe’s Garage Act II & III, “I Don’t Wanna Get Drafted,” You Are What You Is, Ship Arriving too Late to Save a Drowning Witch, The Man from Utopia, London Symphony Orchestra Vol. I, Them or Us, Meets the Mothers of Prevention, Jazz from Hell.

[business-market-insight]

North America Biopharmaceuticals Market, Size, Segment and Growth by Forecast Period: 2023-2028

The North American biopharmaceuticals market, valued at US$ 151.22 billion in 2022, is projected to reach US$ 315.74 billion by 2028, exhibiting a Compound Annual Growth Rate (CAGR) of 13.1% from 2022 to 2028. This growth is significantly fueled by the increasing potential to treat rare diseases. 📚Download Full PDF Sample Copy of Market Report @https://www.businessmarketinsights.com/sample/BMIRE00028630

According to the National Institute of Health (NIH), approximately 10% of the US population (30 million Americans) is affected by one of the 7,000 known rare diseases. While developing treatments for these conditions presents scientific and operational complexities due to their intricate biology, biopharmaceutical researchers in North America have made significant strides, leveraging new technologies to develop groundbreaking therapies. Over the past decade, the US FDA has approved 350 orphan drugs, particularly for conditions with limited or no existing treatments. For instance, Transthyretin amyloid cardiomyopathy (ATTR-CM), a rare and progressive cardiovascular disease with a median life expectancy of only 2.5-3.5 years if untreated, is a prime target for these advancements. Furthermore, Ultragenyx Pharmaceutical Inc. is actively involved in clinical studies (initiated December 2021) for UX053, an mRNA-based therapy for Glycogen Storage Disease (GSD) type 3, a severe rare genetic disorder. UX053 aims to be the first potential medicine for GSD3, capable of delivering large genes to targeted cells for high protein expression uniformity, with plans for individualized mRNA therapies. Such clinical developments, product launches, and approvals are significantly propelling the North America biopharmaceuticals market.

Geographically, the North America biopharmaceuticals market encompasses the US, Canada, and Mexico. The region's market expansion is primarily driven by the rising incidence of cancer, the continuous introduction of new products, and technological advancements within the biopharmaceutical sector. The biopharmaceuticals industry is at a critical juncture, holding immense promise for revolutionizing the treatment of costly and debilitating diseases such as Alzheimer's, cancer, heart disease, and hepatitis C.

The US plays a pivotal role in this growth, driven by a growing burden of chronic diseases and substantial investments in research and development. The US leads globally in R&D investment and innovation, with over 3,400 drugs in clinical development as of 2020, representing nearly half of the estimated 8,000 drugs worldwide (including 1,100 for various cancers). The biopharmaceuticals industry contributes significantly to the US economy, both directly and indirectly. In 2018, pharmaceutical and medical manufacturing accounted for 0.95% of private sector value added, with biotech R&D facilities contributing an additional 0.23%. The high prevalence of chronic conditions further underscores the market's potential; for example, data from the Centers for Disease Control and Prevention (CDC) in July 2022 indicated that approximately 20.1 million adults aged 20 and older in the US suffer from coronary artery disease, with nearly 805,000 Americans experiencing a heart attack annually. These factors are expected to substantially boost the North America biopharmaceuticals market throughout the forecast period.

North America Biopharmaceuticals Strategic Insights

Strategic insights for the North America Biopharmaceuticals provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Market leaders and key company profiles   AbbVie Inc

  AGC Biologics AS

  Amgen Inc

  Boehringer Ingelheim International GmbH

  Bristol-Myers Squibb Co

  Eli Lilly and Co

  Johnson & Johnson

  Lonza Group AG

  Thermo Fisher Scientific Inc

  WuXi Biologics Inc North America Biopharmaceuticals: Tailoring Strategies for Regional Success

Understanding the distinct geographic landscapes within North America is paramount for biopharmaceutical companies. Local variations in consumer preferences (e.g., demand for specific treatments or healthcare services), economic conditions, and regulatory environments necessitate a tailored approach. By recognizing these regional differences, businesses can identify underserved markets, adapt their offerings to meet specific local demands, and optimize resource allocation. A clear market focus enables more effective targeted marketing and stronger competitive positioning, ultimately driving growth across North American biopharmaceutical markets.

The North America biopharmaceuticals market is categorized by product type, application, and country.

Product Type Segmentation:

Monoclonal Antibodies: Held the largest market share in 2022.

Recombinant Vaccines:

Cancer vaccine

Malaria vaccine

Ebola vaccine

Hepatitis-B vaccine

Tetanus vaccine

Diphtheria vaccine

Cholera vaccine

Others

Conventional Vaccines:

Polio vaccine

Pox vaccine

Others

Recombinant Growth Factors:

Erythropoietin

Granulocyte colony stimulating factor

Purified Proteins:

Leukemia inhibitory factor (LIF)

P53 protein

P38 protein

Others

Recombinant Proteins:

Serum albumin

Amyloid protein

Defensin

Transferrin

Recombinant Hormones:

Recombinant human growth hormones

Recombinant insulin

Other recombinant hormones

Recombinant Enzymes:

Enterokinase

Cyclase

Caspase

Cathepsin

Cell & Gene Therapies:

Allogenic products

Autologous products

Acellular products

Cytokines/Interferon/Interleukins

Others

Application Segmentation:

Oncology: Held the largest market share in 2022.

Inflammatory & Infectious Disease

Autoimmune Disorders

Metabolic Disorders

Hormonal Disorders & Growth Failure

Cardiovascular Diseases

Neurological Diseases

Others

Country Segmentation:

US: Accounted for the largest market share in 2022.

Canada

Mexico

Key Players in the North America Biopharmaceuticals Market:

AbbVie Inc

AGC Biologics AS

Amgen Inc

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Co

Eli Lilly and Co

Johnson & Johnson

Lonza Group AG

Thermo Fisher Scientific Inc

WuXi Biologics Inc

About Us: Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Défense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications Author's Bio Akshay Senior Market Research Expert at Business Market Insights

[bisresearch0]

Latin America NGS Market - Analysis and Forecast, 2024-2034 

The Latin America next-generation sequencing (NGS) market refers to the comprehensive application of NGS technologies for clinical diagnostics, translational research across Latin American countries. This market includes instruments, such as sequencers, and consumables, such as reagents, kits, software, and services. 

Next-generation sequencing (NGS) is transforming healthcare by enabling comprehensive genomic analysis for personalized medicine. NGS facilitates the use of targeted medicines, accurate tumor profiling, and the discovery of actionable mutations in oncology. Through the use of circulating tumor DNA, it enables non-invasive cancer surveillance in liquid biopsies. Rapid pathogen identification and non-invasive prenatal diagnostics also depend on NGS. The use of NGS is accelerating in Latin America due to the increased rates of genetic diseases and cancer. With the help of public-private partnerships, nations like Brazil and Mexico are making investments in precision medicine and genomic testing. The Latin American NGS industry is expected to grow significantly as clinical laboratories use NGS into diagnosis and research collaborations increase.

In 2024, The Latin America NGS Market was valued at $268.04 million. It is projected to grow at a compound annual growth rate (CAGR) of 8.34%, reaching $597.20 million by 2034.

Key Emerging Trends

Growing Interest in Personalized Medicine: NGS is being widely used in the region for research on infectious diseases and cancer, especially for precision diagnostics. NGS is essential for virology and mutation detection, including in illnesses like COVID-19.

Developing Local Infrastructure: Countries in Latin America are making investments to build up their own genomics talent and infrastructure. To lessen reliance on foreign platforms, initiatives such as Mexico's CABANA model are assisting in the construction of genomic centers and bioinformatics training.

Improved Accessibility of Genomic Data: Localized genetic data is becoming more accessible because to cooperative initiatives in nations like Mexico and Brazil. In order to promote more equitable and accurate research outputs for local communities, companies like as Lifebit, Omica.bio, and gen-t are assisting in ensuring greater representation in global datasets.

Market Segmentation

By Offering

Instruments

Kits and Consumables

Software

Services

By Technology

Ion Torrent Semiconductor Sequencing

Reversible Terminator Sequencing (SBS)

Single Molecule Real-Time Sequencing

Nanopore Sequencing Technologies

By Application

Clinical

Translational Research

By End User

Hospitals and Clinics

Academic and Research Institutes

Pharmaceutical and Biotechnology Companies

Government Labs

Major Market Challenges

High Costs: The high cost of NGS testing is still a major obstacle in Latin America, particularly in lower-income countries like Brazil, Mexico, and Argentina, even if prices are declining globally. Wider integration into national healthcare systems is hampered by this.

Inadequate Finances and Compensation: Investments in genetic testing infrastructure are constrained by public healthcare institutions' limited financial resources. As a result, clinical adoption is further hampered by poor reimbursement rates and continued reliance on pricey private laboratories.

Professional and Educational Gaps: Patients and healthcare professionals are notably unaware about the potential and advantages of genetic technologies. Widespread adoption in nations like Brazil is also further delayed by a lack of qualified personnel and ambiguous clinical recommendations.

Get Informed: Explore the Influence of Increasing Investments in The Latin America NGS Market Market – Access Our Sample Report!

Learn more about Healthcare Vertical. Click Here!

Conclusion

The growing desire for customized treatment, improved local infrastructure, and growing collaborations in genomic research are driving the Latin American NGS market's encouraging growth trajectory. Even if there are still issues like high expenses, a lack of funding, and a lack of workers, continued investments and clever partnerships are opening the door for wider usage.

Over the next ten years, Latin America is anticipated to emerge as a major force in the global healthcare genomics arena thanks to enhanced accessibility, greater educational opportunities, and the development of regional genomic capabilities.

[blogstrendz]

The Crucial Role of Coactive Coaches in Cancer Recovery

Cancer is more than just a physical disease—it’s an emotional, mental, and lifestyle challenge that requires comprehensive support. 

While medical treatments like chemotherapy, radiation, and surgery are critical, research increasingly shows that lifestyle modifications can significantly influence recovery, reduce side effects, and even lower mortality risks. 

Yet, despite the evidence, integrating these changes into a patient’s daily life remains a challenge.

This is where Coactive Coaches step in—trained professionals who provide personalized, daily guidance to cancer patients, survivors, and high-risk individuals. 

They are not just advisors but companions in the recovery journey, helping patients adopt and sustain healthier habits in nutrition, physical activity, and stress management. Their role is so pivotal that they can no longer be overlooked in modern cancer care.

The Science Behind Lifestyle Interventions in Cancer Care

Decades of clinical research have demonstrated that structured lifestyle changes can:

Reduce cancer recurrence by up to 35%

Lower mortality rates by 37%

Decrease treatment side effects by 37%

Improve sleep quality by 27%

Lessen pain by 18%

These numbers are not just statistics—they represent real improvements in patients' lives. However, most oncology practices lack the infrastructure to provide continuous lifestyle support. Patients are often told to "eat healthier" or "exercise more," but without personalized, sustained guidance, these recommendations rarely translate into lasting habits.

Why Coactive Coaches Are Different

Unlike generic wellness programs, Coactive Coaches work within a clinically validated framework, tailoring interventions based on:

Cancer type and stage

Treatment phase (pre-, during, or post-therapy)

Side-effect profile

Personal preferences and daily routines

This approach ensures that recommendations are medically sound, practical, and aligned with leading oncology guidelines, such as those from the American Institute for Cancer Research (AICR).

But what truly sets them apart is their high-touch, one-on-one support. Cancer patients often face fatigue, anxiety, and fluctuating motivation, factors that make independent lifestyle changes difficult. 

A coach provides not just expertise but also accountability and emotional support, helping patients stay consistent even on the toughest days.

The Human Element in Cancer Recovery

Medical treatments target the disease, but recovery is a holistic process. A patient undergoing chemotherapy may struggle with nausea, making healthy eating seem impossible. Someone recovering from surgery might fear movement, avoiding exercise altogether. 

A survivor may face lingering anxiety about recurrence, impacting sleep and mental health.

Coactive Coaches address these challenges with empathy and adaptability. They don’t just prescribe a diet plan—they help modify it based on a patient’s changing symptoms. 

They don’t just recommend exercise—they adjust intensity based on energy levels. This dynamic, patient-centered approach is what leads to 90% program adherence rates, far exceeding typical wellness interventions.

The Healthcare System’s Blind Spot

Despite the proven benefits of lifestyle medicine, it remains underutilized in oncology. Reasons include:

Lack of reimbursement models for lifestyle coaching in cancer care.

Time constraints in clinical settings mean that oncologists focus on treatment over prevention.

Skepticism about patient compliance outside structured programs.

This gap leaves patients navigating recovery largely on their own. 

Yet, early data suggest that integrating Coactive Coaches into cancer care could reduce healthcare costs by up to 30% by preventing complications, reducing hospitalizations, and improving long-term outcomes.

The Way Forward

Companies like Complement 1, which recently secured $16 million in seed funding, are working to make Coactive Coaching more accessible. Their tech-enabled platform combines AI-driven personalization with human-led coaching, ensuring scalability without sacrificing the human touch.

But beyond funding and technology, the real shift must come in how we view cancer care. Recovery isn’t just about eradicating cancer cells—it’s about rebuilding a patient’s life. 

Coactive Coaches fill a critical void in this process, offering the daily support, expertise, and encouragement that medical teams often can’t provide.

Final Thoughts

Cancer recovery is a marathon, not a sprint. While doctors, nurses, and therapists play irreplaceable roles, Coactive Coaches are the steady companions who walk alongside patients every step of the way. 

Ignoring their role means overlooking a proven way to improve survival rates, reduce suffering, and empower patients to reclaim their health. In the fight against cancer, every ally matters—and Coactive Coaches have earned their place at the table.

Their contribution isn’t just complementary—it’s essential.

[rahuljenaurologist]

Early Signs of Prostate Cancer: What Every Man Should Know

Prostate cancer is one of the most common cancers affecting men worldwide. According to the Indian Council of Medical Research (ICMR), prostate cancer accounts for nearly 7% of all male cancers in India, with rising incidence due to increased life expectancy and improved diagnostic techniques. Early detection is crucial, as prostate cancer often develops silently in its initial stages.

Dr. Rahul Jena, a leading Consultant Uro-oncologist and Robotic Surgeon at Bagchi Sri Shankara Cancer Centre and Research Institute, Bhubaneswar, emphasizes that recognizing early signs can significantly improve treatment outcomes.

In this comprehensive guide, we will explore:

Key statistics on prostate cancer

Early warning signs every man should watch for

Risk factors and screening recommendations

Expert insights from Dr. Rahul Jena

Real-world patient experiences

Understanding Prostate Cancer: Key Statistics

Before diving into symptoms, it’s essential to understand the prevalence and impact of prostate cancer:

Global Burden: Prostate cancer is the second most common cancer in men worldwide, with over 1.4 million new cases annually (GLOBOCAN 2020).

Indian Scenario: In India, prostate cancer incidence has doubled in the last 25 years, with higher rates in urban areas due to lifestyle changes.

Age Factor: The risk increases significantly after age 50, with 60% of cases diagnosed in men over 65.

Survival Rates: When detected early, the 5-year survival rate exceeds 95%, but drops sharply if cancer spreads.

These statistics highlight why awareness of early symptoms is vital.

Early Signs of Prostate Cancer: What to Look For

Prostate cancer symptoms often mimic benign conditions like Benign Prostatic Hyperplasia (BPH), making them easy to overlook. Dr. Rahul Jena advises men to watch for these key early indicators:

1. Urinary Changes

The prostate surrounds the urethra, so tumors can press against it, causing:

Weak or interrupted urine flow

Frequent urination, especially at night (nocturia)

Difficulty starting or stopping urination

Burning sensation or pain during urination

Case Example: A 58-year-old patient in Bhubaneswar ignored mild urinary hesitancy for months, assuming it was age-related. Later diagnosis revealed early-stage prostate cancer, treatable with robotic surgery.

2. Blood in Urine or Semen (Hematuria/Hematospermia)

While not always cancerous, blood in urine (hematuria) or semen (hematospermia) warrants immediate medical evaluation.

3. Erectile Dysfunction (ED)

Prostate cancer can affect nerves and blood vessels essential for erections. While ED is common with age, sudden onset should be investigated.

4. Pelvic, Hip, or Lower Back Pain

Persistent discomfort in the pelvis, hips, or lower back may indicate cancer spread to bones—a sign of advanced disease.

5. Unexplained Weight Loss and Fatigue

Non-specific symptoms like fatigue and weight loss can signal aggressive prostate cancer affecting metabolism.

Risk Factors: Who is Most Vulnerable?

While any man can develop prostate cancer, certain factors increase risk:

Age: 90% of cases occur in men over 55.

Family History: A father or brother with prostate cancer doubles your risk.

Race: African-American men have the highest incidence globally.

Diet & Lifestyle: High-fat diets, obesity, and smoking may contribute.

Dr. Rahul Jena’s Insight: “Men with a family history should start screening at 40. Others can begin at 50, but those with symptoms should not delay consultation.”

Screening and Diagnosis: When to See a Doctor

Early detection relies on two primary tests:

Prostate-Specific Antigen (PSA) Test: Measures PSA levels in blood; elevated levels may indicate cancer.

Digital Rectal Exam (DRE): A physical exam where a doctor checks for prostate abnormalities.

Controversy Around PSA Testing:

False positives can lead to unnecessary biopsies.

Overdiagnosis may detect slow-growing cancers that don’t need treatment.

Dr. Jena’s Approach: “We use multiparametric MRI and targeted biopsies to reduce unnecessary procedures. Personalized screening is key.”

Real-World Cases: Why Early Action Matters

Case 1: Delayed Diagnosis Leads to Advanced Cancer

A 65-year-old farmer in Odisha ignored urinary symptoms for years, assuming they were due to aging. By the time he sought help, cancer had spread to his bones, limiting treatment options.

Case 2: Early Detection Saves Lives

A 52-year-old executive undergoing routine check-ups had a slightly elevated PSA. Further tests confirmed localized cancer, treated successfully with robotic prostatectomy.

Prevention and Next Steps

While not all prostate cancers are preventable, these steps can help:

Eat a balanced diet (rich in tomatoes, green tea, and omega-3s)

Exercise regularly

Avoid smoking and excessive alcohol

Get regular screenings if at high risk

Dr. Rahul Jena’s Final Advice: “Don’t dismiss urinary changes as ‘just aging.’ Early consultation can mean the difference between curable and advanced cancer.”

Conclusion: Knowledge is Power

Prostate cancer is highly treatable when caught early. By recognizing symptoms early, understanding risk factors, and seeking timely medical advice, men can significantly improve their outcomes.

If you or a loved one experiences any warning signs, consult a urologist or uro-oncologist like Dr. Rahul Jena for expert evaluation.

Your health today determines your future—take action before it’s too late.

About Dr. Rahul Jena

Dr. Rahul Jena is a renowned Consultant Uro-oncologist and Robotic Surgeon at Bagchi Sri Shankara Cancer Centre and Research Institute, Bhubaneswar. With expertise in minimally invasive cancer surgeries, he is dedicated to advancing prostate cancer care in Eastern India.

[trump-executive-orders]

Cancer Control Month, 2025

Issued April 3, 2025.

During Cancer Control Month, we honor the unwavering strength and courage of every American battling cancer and celebrate with over 18 million survivors who are still with us today.  We also hold dear the memories of beloved family members and friends that we have lost to this devastating disease.  My Administration remains devoted to pursuing groundbreaking medical advancement and spearheading innovative treatments to combat and prevent all forms of cancer.

Last year, over 2 million Americans were diagnosed with cancer, and more than 600,000 lost their lives to this horrific disease.  Since 1990, adult cancer cases have surged by 88 percent, while childhood cancer cases, though still uncommon, has incrementally increased by 0.8 percent annually since 1975, leading to a more than 40 percent increase in the past 50 years.  These trends indicate that something is wrong.  That is why I have proudly established the Make America Healthy Again Commission to address the root causes of America’s chronic disease crisis.

My Administration is committed to lowering healthcare costs; making additional treatment options available through Right to Try; and rooting out waste, fraud, and abuse in Government.  By promoting transparency and ending conflicts of interest in federally funded health research, we are working to restore trust in our medical and scientific institutions.  As President, I am also tapping into emerging technologies like artificial intelligence to support cutting-edge research in innovative fields like genomics and immunotherapy, pioneering medical advances that will improve the lives of cancer patients. 

Cancer is the second leading cause of death in the United States.  However, there are encouraging signs of progress.  The combined death rate from all types of cancer continues to decline among both men and women, and the mortality rates for several common cancers — including lung, colon, breast, and ovarian — are steadily decreasing.  These promising developments reflect the unending efforts of our Nation’s dedicated healthcare professionals to diagnose cancers at earlier stages, improve prevention, and enhance treatment.

Americans must take action to prevent and combat cancer.  Maintaining a healthy weight, adopting balanced eating habits, and engaging in regular physical activity may help prevent kidney, endometrial, esophageal, colorectal, and other cancers.  Avoiding tobacco use and alcohol consumption can also help prevent and combat cancers.  Additionally, Americans should discuss their family medical history with their doctors and undergo recommended screenings.  This can lead to an early diagnosis and increase the odds of overcoming the disease.

As a country, we will continue to push the boundaries of medical innovation, driven by the unwavering spirit of the American people.  Together, we will work to vanquish cancer, eradicating the suffering and pain it has inflicted on too many American families.  I have unshakable faith in the greatness of our Nation and the excellence of our people.  We will continue to fight until we find a long-sought cure, and we will emerge victorious in our fight against cancer.

The Congress of the United States, by joint resolution approved March 28, 1938 (52 Stat. 148; 36 U.S.C. 103), as amended, has requested the President to issue an annual proclamation declaring April as “Cancer Control Month.”

NOW, THEREFORE, I, DONALD J. TRUMP, President of the United States of America, by virtue of the authority vested in me by the Constitution and the laws of the United States, do hereby proclaim April 2025 as Cancer Control Month.  I call upon the people of the United States to observe this month with relevant programs, ceremonies, and activities.

IN WITNESS WHEREOF, I have hereunto set my hand this third day of April, in the year of our Lord two thousand twenty-five, and of the Independence of the United States of America the two hundred and forty-ninth.

[nursingwriter]

Supplements, Fatigue and Lethargy DO THEY HELP? Vitamin E (p 1- 1.5) Vitamin E is a fat-soluble vitamin and antioxidant, which inhibits the production of reactive oxygen species or ROS when fat is oxidized (NIH, 2013). The body produces ROS when it converts food into energy. As an antioxidant, Vitamin E protects body cells from the ill effects of free radicals. Free radicals are molecules containing an unshared electron. They damage cells and contribute to the development of heart diseases and cancer. Unshared electrons are very active and quickly react with oxygen to form ROS. Health experts conjecture that limiting the production of free radicals may, alone or through other mechanisms, help prevent or delay the formation of these dreaded chronic diseases associated with the action of free radicals. Vitamin E may serve that function (NIH). As an antioxidant, it also plays a role in the immune function of the body (NIH, 2013). In vitro studies of cells have illustrated its role in cell signaling, regulating gene expression and other metabolic processes. As Alpha-tocopherol, it inhibits the activity of the protein kinase C, which is an enzyme that participates in cell proliferation and differentiation of smooth muscle cells, platelets and monocytes. Alpha-tocopherol is its only form that is suitable for human needs (NIH). The recommended intake of Vitamin E as well as other nutrients is developed by the Food and Nutrition Board and listed under the Dietary Reference Intakes (NIH, 2013). The intake depends on age and gender from 4-19 mg. The recommended dietary allowance for those 14 years old and older is 19 mg. The vitamin in the form of alpha-tocopherol has many food sources and best among them are nuts, vegetable oils, green leafy vegetables and fortified cereals. It is present in the American diets in the form of gamma tocopherol. It can be obtained from soybean, canola, corn and other vegetable oils and food products. Wheat germ oil is an excellent natural source (NIH). Many have claimed that Vitamin E protects against coronary heart disease, cancer, eye disorders like age-related macular degeneration and cataract, and cognitive decline (NIH, 2013). Research says that healthy or slightly ill persons need not take Vitamin E supplements to increase cognitive abilities or retard aging. While no adverse effects have been shown from consuming the vitamin in food form, high doses of alpha-tocopherol supplements have, in some cases, caused hemorrhage, interrupted blood coagulation and platelets or inhibited blood coagulation in animals (NIH). Unit 4: Supplements and Lethargy Fatigue and Felicia's Case Felicia's fatigue is unlikely connected with any need to take supplements for energy. Women's fatigue is one of the top five health concerns of women, according to a recent health survey (Watson, 2014). More likely, Felicia's fatigue is the symptom of seven possible causes common to women. These are thyroid problems, heart disease, Vitamin D deficiency, iron-deficiency anemia, sleep apnea, lack of sleep and depression (Watson). Thyroid problems appear to be more common in women than in men for still unknown reasons (Watson, 2014). The thyroid produces the hormones, which regulate the body's burning of fuel for energy. The thyroid may be overactive or under-active and sleepiness is a symptom of both. Vitamin D deficiency drains bone strength and may even lead to chronic fatigue syndrome. A blood test can detect this problem. The Institute of Medicine determined that most adults will avoid these problems by taking 600 international units a day. Those aged 70 or older should take 800 IU. Iron-deficiency anemia limits the amount of oxygen in the body and leads to sluggishness. A woman may be losing too much blood when menstruating or she may be outright deficient in other vitamins and minerals. Supplements will easily help. Sleep apnea is another possible cause. It is a condition, which stops one's breathing repeatedly through the night. The brain jolts each time the breathing stops. When sleep does not provide rest, the body does not get the time needed to restore itself and recharge. Lack of sleep results from a very busy day. Most women today suffer from this lack of sufficient sleep because of too many activities. The solution is to do one's best to establish and follow a calming bedtime habit. Induce sleep through soft music, calming scents, a cup of chamomile tea, reading a good book or another relaxing activity for 15 minutes. And the last possible cause is depression. It often goes with fatigue and both of these are more common in women than in men. These two conditions even seem to trigger each other. A depressed woman tends to become tired and a fatigued woman is thrice as likely to be depressed, according to studies. Treating the cause of the depression will do a lot to eliminate the fatigue rather than take supplements (Watson). Fred's Case Rather than vitamin deficiency or any other deficiency, the cause of Fred's sudden lethargy, reduced coordination and slight confusion may be andropause (Bain, 2001). It is male menopause, which corresponds to women's menopause. This observation has attracted widespread attention in the last few years. It suggests that as men age, their testosterone levels, like women's hormones, gradually fall. The decline occurs sharply with every decade after 30 (Bain). This observation applies to Fred who is 69. Research says that aging men start to experience new symptoms, such as sexual dysfunction, weakness, fatigue, lethargy, insomnia, mood disorders, flushes and reduced motivation. Another symptom is the loss of bone density, which they may not realize or know until they suffer from a fracture. Aging men's testosterone levels decline as they age. At this stage, they usually need testosterone replacement therapy in order to reduce these symptoms. Present evidence suggests that treating men with these symptoms due to low testosterone will often raise their overall sense of well-being and quality of life and deal with lethargy, as in Fred's case (Bain). A recent study was conducted to develop a rationale for treating aging men with these symptoms and whose testosterone levels are mildly-reduced or low-normal with testosterone replacement therapy (Bain, 2001). The study could not locate large-scale and multi-center prospective studies on the value of treating andropausal men with hormone therapy. This is because the whole discipline of hormone therapy was only a decade old when this study was conducted. It used physiologic, open uncontrolled studies of treatments, which have been assessed. These limited studies reveal that testorterone treatment has very few serious side effects (Bain). When examining Fred, his physician should consider hypoandrogenism for his lethargy, reduced coordination, slight confusion and cognitive troubles (Bain, 2001). These are among the symptoms of andropause. The main cause of his reduced testosterone production is technically primary gonadal insufficiency. Andropause covers a complex of symptoms in aging men like Fred who now suffers from declining testosterone levels. His physician should be aware of this new experience, order the precise tests for it and treat them carefully (Bain). BIBLIOGRAPHY Bain, J. (2001). Andropause: testosterone replacement therapy for aging men. Vol. 47, Canadian Family Physician: Janvier. Retrieved on February 28, 2014 from http://www.cfp.ca/content/47/1/91.long NIH (2013). Vitamin E Office of Dietary Supplements: U.S. Department of Health & Human Services. Retrieved on February 28, 2014 from http://www.ods.od.nih.gov/factsheets/VitaminE-HealthProfessional Watson, S. (2014). The causes of women's fatigue. WebMD Magazine: WebMD LLC. Retrieved on March 1, 2014 from http://www.webmd.com/women/featuress/the-causes-of-womens-fatigue Read the full article

[ear-worthy]

Curiosity Weekly Podcast: Science The Way You Like It

Discovery Channel, known as The Discovery Channel from 1985 to 1995, and often referred to as simply Discovery, is an American cable channel that used to be known for documentary television programming focused primarily on popular science, technology, and history. Over the years, it has been transformed into a schedule of reality television shows, promotion of pseudoscience, and conspiracy theories. On Discovery, there are people apparently running around naked in the woods and other people searching for gold. The cable channel should merge those shows into one where naked people search for gold. That's why I was worried when one of the board members of Ear Worthy recommended Curiosity Weekly. However, after listening to several episodes, I can safely say: "No cause for alarm. Apparently, Warner Discovery CEO David Zaslov, destroyer of quality content, either doesn't know this podcast is on or doesn't care." 

Here's the show's marketing pitch: "Once a week, we'll bring you the latest and greatest in scientific discoveries." 

That was an encouraging start and, for the most part, they live up to that promise.

Discovery continues: "Welcome to Curiosity Weekly from Discovery, hosted by Dr. Samantha Yammine. Once a week, we’ll bring you the latest and greatest in scientific discoveries and break down the details so that you don’t need a PhD to understand it. From neuroscience to climate tech to AI and genetics, no subject is off-limits. Join Sam as she interviews expert guests and investigates the research guiding some of the most exciting scientific breakthroughs affecting our world today."

The host, Dr. Samantha Yammine, PhD is a Neuroscientist turned Science Communicator, also known as Science Sam. Through social media, TV screens and keynote stages, she has built an engaged community encouraging people to explore science by making it more accessible, inclusive and fun. As a host, Dr. Yammine does an excellent job. She's engaged, witty, informative, and inclusive.

What's on the show? What's the format? Let's discuss.

 The format includes three topics each episode. On the latest February 18th show, watch how Discovery tied content on their MAX streaming service to the podcast.

"The White Lotus is about to be back on our screens on Max, so today, we’re diving into the latest trend among elite travelers: longevity tourism. Then, our host Sam speaks to Dr. Jodi Halpern about the mental health effects that come along with the rise of AI technology. And finally, we explore the ins and outs of fracking."

Since its new format in January, listeners like myself have learned about Multi-Drug Resistant Bacteria found on ISS mutating to become functionally distinct. In one of my favorite segments, left-handed musicians, appear to develop unique brain pathways for language processing. (I knew we were special, and not just because our handwriting sucks.) There was a timely episode on the FDA banning red dye No. 3 from foods, nearly 35 years after it was barred from cosmetics because of potential cancer risk. Then, the show explored the benefits of Emotional Support Animals (ESAs), which is a controversial topic. 

 There are several science podcasts we can also recommend. Big Picture Science. It's a terrific podcast that exposes junk science, highlights new scientific discoveries, and finds the science in everyday life. Big Picture Science is produced at the SETI Institute’s radio studio in Mountain View, California. Short Wave is a National Public Radio (NPR) podcast that gives us a sneak peek behind the science headlines — all in about 10 minutes, every weekday. It's science for everyone, using a lot of creativity and a little humor. If you are a physics nerd, then tryWhy This Universe -- The biggest ideas in physics, broken down. Join theoretical physicist Dan Hooper and co-host Shalma Wegsman as they answer your questions about dark matter, black holes, quantum mechanics, and more. 

If you're interested in real science, then check out Curiosity Weekly.

[literaturereviewhelp]

However, actual research on stem cells began in the 1960s and the 1970’s when treatment of many immunodeficiency conditions and leukemia was sought from stem cells (UK Stem Cell Foundation 2011). In general, at that time, since the scope of stem cell research was huge and could also be life-saving in certain circumstances, people recommended using such technology. Even today, several diseases such as cancer, heart disease, etc, are incurable and a stem cell research may offer a chance. Not only are the people looking towards the government to permit the use of this technology, but also federal funding is being sought to sponsor this technology. In one patient who was suffering from HIV/AIDS, the use of stem cells from a person who had a resistant gene variant helped the patient to stop taking antiviral medications. However, the use of embryonic stem cells poses a lot of ethical issues as they have the potential to form life (Research America 2012). Stem cell research is not pro-life and often the promises that they offer are not evidence-based and only distance possibilities. No cure for any disease has been obtained from stem cell research nor has this form of research proceeded beyond laboratory animals. When George W Bush had taken the office in 2001, he enacted a ban on stem cell research with an intention of ending federal funding on it as it involved destroying human life. Here since human life was being used merely for the sake of experimentation and harvesting body parts, the Congress sought for the ban on stem cells (Wertz, 2002). However, the Congress sought the use of stem cells without destroying embryonic cells that had the potential to transform into human beings. In 2004, the California Institute for Regenerative medicine was setup in order to regulate the research findings and the research facilities. Institutions seeking financing fro stem cell research have to approach the California Institute for Regenerative medicine. In 2007, the Bush Administration sought the reversal of the earlier policy which sought to inhibit the federal spending on stem cell obtained from human embryos. In 2009, Barack Obama signed the executive order that permitted stem cell research on human embryos. In 2011, greater clarification on the federal funding was being sought as federal funds could only be spent on researching stem cells and not destroying the human embryos (American Association for the Advancement of Science 2011). 2. How does it compare to comparable statutes in the rest of the world? The US is not the only nation to have a problem with regulating stem cell research and many other nations including the EU may ban stem cell research derived from embryonic stem cells. Many of the governments across the world have been funding stem cells research. In China, stem cell therapy centers are present which uses stem cells from umbilicus or autologously generated for treating several disorders such as Parkinsonism and cerebral plays. In Australia, informed consent is required from the couple undergoing IVF for stem cell research and only those embryonic cells that are going to be wasted can be used for stem cell research. Read the full article

[weepingbarbariansweets]

North America Stem Cell Therapy Market Size, Share, Company Profiles and Trends Forecast To 2028

The North America stem cell therapy market was valued at US$ 1,299.39 million in 2022 and is projected to reach US$ 3,582.26 million by 2028; it is expected to grow at a CAGR of 18.4% from 2022 to 2028. 

Increasing Research Activities Related to Stem Cell Therapy for Effective Disease Management is Driving the North America Stem Cell Therapy Market

Stem cell therapy has been widely investigated across the world. Stem cells are mainly used to replace dying cells and reconstruct damaged tissues. Based on the results of extensive stem cell research conducted so far, many scientists have claimed that these cells could probably be utilized to generate cures and treatments for diseases such as cancer and cardiovascular disease. Newly developed stem cell therapies involve replacing disease-causing cells with stem cells. Many potential treatments involving stem cells are in different phases of clinical trials. The FDA has also approved a few stem cell therapies involved in treating complications related to stem cell transplants. In September 2021, the US Food and Drug Administration (FDA) announced approval for "Ruxolitinib" for treating "graft-versus-host-disease" (GVHD) in patients aged 12 and above. Ruxolitinib provides a patient new hope that suffers from fatal complications associated with stem cell transplants.

📚𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐂𝐨𝐩𝐲@ https://www.businessmarketinsights.com/sample/BMIRE00028486

Researchers are further investigating the use of stem cell therapy in treating autoimmune disorders. For example, stem cells can turn into the cells of damaged organs and are used in treating autoimmune diseases. Treatment is carried out using mesenchymal stem cells or fetal stem cells. Hematopoietic stem cells are currently used for treating more than 80 medicals conditions, including immune system diseases, blood disorders, neurological disorders, metabolic disorders, genetic disorders, and cancer types such as leukemia and lymphoma.

𝐓𝐡𝐞 𝐋𝐢𝐬𝐭 𝐨𝐟 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬

MEDIPOST

RichSource

BioTime, Inc.

Mesoblast Limited

U.S. Stem Cell, Inc.

TiGenix NV

AlloSource

NuVasive Inc

📚𝐅𝐮𝐥𝐥 𝐑𝐞𝐩𝐨𝐫𝐭 𝐋𝐢𝐧𝐤 @ https://www.businessmarketinsights.com/reports/north-america-stem-cell-therapy-market

Segments Covered

By Type

Adult Stem Cell Therapy

Embryonic Stem Cell Therapy

Induced Pluripotent Stem Cell Therapy

Other Stem Cell Therapy

By Treatment

Allogeneic

Autologous

By Application

Musculoskeletal

Dermatology

Cardiology

Drug Discovery & Development

Other Applications

By End User

Hospitals & Specialty Clinics

Academic & Research Institutes

Empowering Informed Decisions: Driving Profitability:

Ultimately, effective strategic insights empower stakeholders to make informed decisions that drive profitability and achieve their business objectives. By leveraging data-driven analysis, actionable recommendations, and a future-oriented perspective, stakeholders can navigate the complexities of the North American stem cell therapy market and capitalize on its immense potential.

In conclusion, strategic insights are not merely a compilation of data; they are a roadmap for navigating the future of stem cell therapy. They provide the compass and the map needed to guide investment, research, and market penetration, ensuring that stakeholders are not just participants, but leaders in this transformative field.

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬: Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications

[business-market-insight]

North America Wheat Protein Market Trends, Size, Segment and Growth by Forecast to 2030

North American Wheat Protein Market: Growth Driven by Health Trends and Expanding Applications

The North American wheat protein market is poised for significant growth, projected to increase from US$ 952.17 million in 2021 to US$ 1,102.79 million by 2028, demonstrating a compound annual growth rate (CAGR) of 2.1% during this period. This expansion is primarily fueled by a growing consumer focus on health and wellness, coupled with the versatile applications of wheat protein in various industries.

Key Market Drivers

Consumers across North America, particularly in the US and Canada, are increasingly prioritizing a healthy lifestyle, leading to a surge in demand for products offering health benefits. This shift is a major catalyst for the wheat protein market. Wheat is a vital agricultural commodity globally, and North American companies are continually innovating their product portfolios to meet evolving consumer needs. Key players in this market include Cargill Incorporated, MGP Ingredients, Inc., and Archer Daniels Midland Company. 📚Download Full PDF Sample Copy of Market Report @ https://www.businessmarketinsights.com/sample/TIPRE00027191

The rising prevalence of chronic diseases like cardiovascular conditions, high blood pressure, and high cholesterol, often linked to obesity, is also driving the demand for plant-based proteins such as wheat and oat proteins. Non-profit and government organizations like the American Institute for Cancer Research, the 2015–2020 Dietary Guidelines for Americans (DGA), and Health Canada actively promote plant-based diets, further boosting the market.

Impact of the COVID-19 Pandemic

The COVID-19 pandemic initially caused significant disruptions in manufacturing facilities and raw material sourcing, negatively impacting the wheat protein market in North America. Shutdowns of manufacturing units and bakeries further hindered demand. Additionally, the pandemic affected food supply chains, from farm production to processing, transport, and logistics.

However, the pandemic also spurred a positive shift in consumer lifestyles, leading to increased demand for healthy food and beverage products. This heightened focus on health and well-being is now expected to accelerate the demand for wheat protein in the North American market.

Expanding Applications

The burgeoning food and beverage industry is a key driver for the wheat protein market. Wheat protein is increasingly incorporated into nutritional supplements, bakery products, and snacks. Its use in sports and energy drinks is also on the rise, as it aids in enhancing athletic power, strength, and overall physical performance. These diverse applications are significantly contributing to the market's growth trajectory in North America.

Segment

Categories

Key Highlights (2020)

By Product

Wheat Gluten, Wheat Protein Isolates, Textured Wheat Protein, Hydrolyzed Wheat Protein

Wheat gluten held the largest market share.

By Form

Dry, Liquid

Dry form dominated with the highest revenue share.

By Application

Bakery & Snacks, Pet Food, Nutritional Bars & Drinks, Processed Meat, Meat Analogs, Others

Bakery & snacks led the application segment.

By Country

United States, Canada, Mexico

The US accounted for the largest market share.

Key Companies

Archer Daniels Midland, Cargill, Kröner-Stärke, Manildra Group, MGP Ingredients, Roquette, Tereos

Leading market players profiled.

North America Wheat Protein Strategic Insights

Strategic insights for the North America Wheat Protein provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market. North America Wheat Protein Regional Insights The regional landscape of the North America wheat protein market highlights the importance of understanding the unique characteristics of each area in which businesses operate. Factors such as varying consumer preferences (e.g., demand for specific product types or dietary trends), economic conditions, and regulatory frameworks play a vital role in shaping market strategies. By recognizing and adapting to these regional differences, companies can uncover growth opportunities in underserved markets and tailor their product offerings accordingly. A well-defined geographic focus enhances resource allocation, enables more targeted marketing efforts, and strengthens competitive positioning—ultimately supporting sustainable market expansion across North America. About Us: Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Défense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications Author's Bio Akshay Senior Market Research Expert at Business Market Insights

[global-research-report]

Market Dynamics of Ovarian Cancer Diagnostics: Growth Opportunities and Challenges

The global ovarian cancer diagnostics market size is expected to reach USD 6.46 billion by 2030, registering a CAGR of 5.0 % from 2024 to 2030, according to a new report by Grand View Research, Inc. The growth of the market can be attributed to an increase in the prevalence of ovarian cancer and emergence of novel diagnostic products. As of 2018, ovarian cancer had the highest mortality rate of all gynecologic cancers. It accounted for nearly 14,000 deaths in the U.S. in 2018. No specific symptoms render early diagnosis of the disease increasingly difficult. The exact causative factors remain unknown, creating a key unmet need for further research to obtain clarity on the underlying molecular mechanisms.

Women aged 60 years & above have a higher predisposition to it. As it is often diagnosed in advanced stages, treatment options are limited. Moreover, on the basis of race, incidence rates were higher among Caucasian women than African-American women. The International Federation of Gynecology and Obstetrics (FIGO) system is used for staging ovarian cancer. Staging process helps identify ovarian tumors, calculate their size, and detect invasion & metastasis.

Early detection and diagnosis significantly improve patient survival rates. For instance, in case of epithelial tumors, patients with stage 1 ovarian cancer have a survival rate of nearly 90%, whereas patients with stage 4-the most advanced phase-have a mere 15% survival rate. Technological advancements in PET and MRI as well as in diagnosis of BRCA mutations have positively impacted market growth.

The diagnostic landscape is gradually shifting toward genetic testing and counseling. As the disease bears a high risk of inheritance of gene mutation, guidelines pertaining to ovarian cancer diagnostics recommend all patients to undergo genetic counseling and testing. Earlier, BRCA1/2 was the most prominent test; however, advancements in medical science have now made it possible to test more than 20 genes in each patient.

Ovarian Cancer Diagnostics Market Report Highlights

Epithelial tumor held the largest market revenue share in 2023. According to National Library of Medicine, epithelial ovarian tumors, the most common type of ovarian cancer, account for about 95% of all ovarian cancer cases.

The imaging segment held the largest market revenue share in 2023. Advances in imaging technologies, including MRI, CT, and ultrasound, have revolutionized the early detection of ovarian cancer, significantly enhancing their adoption in diagnostic protocols.

The hospital laboratories segment held the highest market revenue share in 2023. Hospitals often collaborate with diagnostic companies, research institutions, and pharmaceutical companies to enhance diagnostic capabilities and develop innovative diagnostic tools for ovarian cancer.

North America ovarian cancer diagnostics market held the largest share of 40.4% in 2023. High healthcare expenditure in North America is driving investments towards advanced diagnostic technologies and infrastructure within cancer diagnostic centers.

Ovarian Cancer Diagnostics Market Segmentation

Grand View Research has segmented the ovarian cancer diagnostics market on the basis of on cancer, diagnosis, end-use, and region:

Ovarian Cancer DiagnosticsOvarian Cancer Diagnostics Cancer Outlook (Revenue, USD Billion, 2020 - 2030)

Epithelial Tumor

Germ Cell Tumor

Stromal Cell Tumor

Others

Ovarian Cancer Diagnostics Diagnosis Outlook (Revenue, USD Billion, 2020 - 2030)

Imaging

Ultrasound

CT Scan

MRI Scan

PET Scan

Others

Blood Test

CA125

HER2

BRCA

CEA

ER & PR

KRAS Mutation

Others

Biopsy

Others

End-use Outlook (Revenue, USD Billion, 2020 - 2030)

Hospital Laboratories

Cancer Diagnostic Centers

Research Institutes

Others

Regional Outlook (Revenue, USD Billion, 2020 - 2030)

North America

US

Canada

Mexico

Europe

Uk

Germany

France

Italy

Spain

Denmark

Sweden

Norway

Asia Pacific

China

Japan

India

Australia

South Korea

Thailand

Latin America

Brazil

Argentina

Middle East and Africa (MEA)

UAE

South Arabia

South Africa

Kuwait

Order a free sample PDF of the Ovarian Cancer Diagnostics Market Intelligence Study, published by Grand View Research.

[quirksphere]

Fluoride Myths and Facts: What You Should Know

Fluoride is a hot topic in health conversations, often surrounded by both strong advocacy and skepticism. It’s widely used in dental care and public water systems to combat tooth decay, but misinformation about its safety and efficacy persists. Here, we’ll debunk some common myths about fluoride and clarify the facts to help you make informed decisions.

Myth #1: Fluoride Is a Harmful Chemical

Fact: Fluoride is a naturally occurring mineral found in water, soil, and various foods. It’s not an artificial chemical concocted in a lab. When used in appropriate amounts, fluoride strengthens tooth enamel and helps prevent cavities.

The confusion often arises because anything can be harmful in excessive doses—even water! Regulatory bodies like the World Health Organization (WHO), American Dental Association (ADA), and Centers for Disease Control and Prevention (CDC) ensure that fluoride levels in drinking water and dental products are safe for human use.

Myth #2: Fluoride in Water Causes Fluorosis

Fact: Dental fluorosis, a condition that causes faint white spots on teeth, can occur if excessive fluoride is consumed during childhood when teeth are developing. However, the fluoride levels in public water supplies are carefully regulated to minimize this risk.

In most cases, dental fluorosis is mild and purely cosmetic. Severe fluorosis is rare in regions with regulated fluoride programs. Educating parents about proper fluoride use, like avoiding swallowing toothpaste, can prevent overexposure.

Myth #3: Fluoride Doesn’t Actually Prevent Cavities

Fact: Decades of research and real-world data have shown that fluoride significantly reduces tooth decay. Fluoride works by remineralizing tooth enamel, making it more resistant to acid attacks from bacteria.

According to the CDC, fluoridated water alone can reduce the incidence of cavities by about 25% over a lifetime. Dental products like toothpaste, mouth rinses, and professional treatments amplify this protective effect.

Myth #4: Fluoride Is Linked to Serious Health Issues Like Cancer

Fact: Claims linking fluoride to conditions like cancer, kidney disease, or cognitive impairments are often based on flawed or inconclusive studies. High-quality, peer-reviewed research has consistently found no credible evidence to support these claims when fluoride is used within recommended levels.

For example, the National Cancer Institute states that fluoridated water does not increase cancer risk. Similarly, large-scale studies on human populations have shown no significant link between fluoride exposure and adverse health outcomes.

Myth #5: We Don’t Need Fluoride Anymore Because of Modern Oral Hygiene

Fact: While modern oral hygiene practices, such as regular brushing and flossing, are vital, they’re not always enough to prevent cavities. Fluoride acts as an additional line of defense, especially for populations with limited access to dental care.

In communities where water fluoridation has been discontinued, dental decay rates tend to rise. This underscores fluoride’s importance as a public health measure.

How to Use Fluoride Safely

Here are some tips to maximize the benefits of fluoride while minimizing risks:

Use Fluoridated Toothpaste: Brush twice daily with fluoride toothpaste, but only use a pea-sized amount for children under six to avoid swallowing.

Drink Fluoridated Water: If your community water supply is fluoridated, it’s an easy and safe way to protect your teeth. If not, talk to your dentist about fluoride supplements.

Visit Your Dentist Regularly: Professional fluoride treatments can provide added protection, especially if you’re at high risk for cavities.

Conclusion

Fluoride is a proven, effective tool in the fight against tooth decay. While myths and misinformation can be concerning, the scientific consensus is clear: fluoride, when used responsibly, is both safe and beneficial. Educating yourself with evidence-based information is the best way to ensure you and your family enjoy optimal oral health.

If you have concerns about fluoride, speak with a trusted dental professional who can address your questions and help you make the best choice for your oral care.

By staying informed, you can confidently embrace fluoride’s benefits and maintain a bright, healthy smile for years to come!

[rakshakulkarni]

AI in Oncology Market to Reach $4.5 Billion by 2031, Growing at a CAGR of 18.8%

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global AI in Oncology  Market- (Type of Cancer (Solid malignancies, Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Brain tumor, Others), By End User (Hospitals, Pharmaceutical companies, Research Institutes, Others)), By Region, Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global AI in Oncology Market is valued at US$ 1.2 Bn in 2023, and it is expected to reach US$ 4.5 Bn by 2031, with a CAGR of 18.8% during the forecast period of 2024-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2529

Utilizing advanced algorithms and machine learning techniques, artificial intelligence (AI) in oncology elevates cancer diagnosis, treatment, and patient care. By analyzing vast medical datasets, AI discerns nuanced patterns to offer tailored treatment suggestions, thereby optimizing patient outcomes. Tools like machine learning algorithms, deep learning techniques, NLP, computer vision, and genomics analysis contribute to this comprehensive approach, improving diagnostic accuracy and treatment outcomes while optimizing healthcare efficiency.

The importance of AI in oncology stems from its diverse capabilities. By enhancing diagnostic accuracy through pattern recognition and tailoring treatment recommendations to individual patient data, AI improves patient outcomes. Furthermore, AI enables proactive interventions by identifying health risks from patient data, enhancing overall patient care. Additionally, AI streamlines healthcare processes, reducing costs and serving as a transformative influence in oncology and broader healthcare contexts.

List of Prominent Players in the AI in Oncology Market:

Berg

CancerCenter.AI

Concert AI

GE Healthcare

IBM Watson Health

iCAD

JLK Inspection

Median Technologies

Path AI

Roche Diagnostics

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2024-02

AI in Oncology Market Report Scope:

Report Attribute

Specifications

Market Size Value In 2022

USD 1.2 Bn

Revenue Forecast In 2031

USD 4.5 Bn

Growth Rate CAGR

CAGR of 18.8 % from 2024 to 2031

Quantitative Units

Representation of revenue in US$ Bn and CAGR from 2024 to 2031

Historic Year

2019 to 2023

Forecast Year

2024-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Type of Cancer, By Type of End Users and By Region

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia

Competitive Landscape

Berg, CancerCenter.AI, Concert AI, GE Healthcare, IBM Watson Health, iCAD, JLK Inspection, Median Technologies, Path AI, Roche Diagnostics, Other Prominent Players

Customization Scope

Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape.

Pricing and Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

Market Dynamics:

Drivers:

The rising incidence of various cancers globally, such as lung, breast, prostate, colorectal cancer, and brain tumors, serves as a significant driver for the AI in oncology market. With statistics provided by the American Cancer Society in 2024, including an estimated 234,580 new cases of lung cancer and 125,070 deaths in the US alone, this trend is underscored. Additionally, the World Health Organization's revelation of nearly 20 million new cancer cases reported annually worldwide further highlights the pressing need for advanced solutions in oncology. Leveraging AI algorithms for precision medicine approaches, analyzing complex genomic and patient data, alongside advancements in medical imaging and data analytics, is crucial for enhancing cancer diagnosis, treatment planning, and overall patient care.

Challenges:

The integration of artificial intelligence (AI) in oncology faces several challenges that impede its widespread adoption and effectiveness in clinical settings. Difficulty in obtaining large, high-quality, multi-institutional datasets and the lack of standardization in data collection within electronic health records (EHRs) inhibit the development and utilization of AI models. Moreover, inconsistent or poor-quality imaging data can lead to erroneous diagnoses and treatment plans, hindering patient outcomes. Labour-intensive tumor segmentation and annotation processes further limit the adoption of AI solutions. Additionally, the lack of standardization and interoperability across healthcare systems poses obstacles to translating AI into real clinical settings. Furthermore, the multidisciplinary nature of AI implementation, requiring collaboration between oncologists, radiologists, and data scientists, presents challenges.

Regional Trends:

North America emerges as a leading region in the advancement of AI technologies within oncology, driven by several key factors. With a projected 2,001,140 new cancer cases and 611,720 cancer deaths in 2024 in the United States alone, North America benefits from an advanced healthcare infrastructure, boasting cutting-edge medical imaging technologies and robust electronic health records. Moreover, the region's significant investment in research and development, facilitated by numerous research institutions and universities, fuels innovation in AI algorithms and technologies tailored for oncology. Additionally, North America's large patient population affected by cancer fuels demand for advanced diagnostic and treatment solutions, met by the adoption of AI technologies. Supported by a strong regulatory framework, including favorable reimbursement policies, North America sets the stage for widespread adoption and integration of AI in oncology, ultimately improving patient outcomes and reducing healthcare costs.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2529

Recent Developments:

In May 2024, ConcertAI launched CARA AI, its advanced predictive and generative AI suite, at the 2024 ASCO Annual Meeting, offering multi-modal data management and fostering collaborative research efforts across translational to clinical development stages. Additionally, ConcertAI introduced an update to its SmartLinQ oncology quality management platform, TriaLinQ.

In May 2024, GE Healthcare introduces Revolution RT, its new AI-enhanced oncology solution, marking a "new era" in radiation therapy computed tomography (CT). Revolution RT features innovative hardware and software to enhance imaging accuracy and streamline simulation workflows, aiming to personalize and simplify the oncology care pathway for clinicians and patients. The technology debuted at the European Society for Therapeutic Radiology and Oncology 2024 Congress in Glasgow, Scotland.

Segmentation of AI in Oncology Market-

By Type of Cancer

Solid malignancies

Breast cancer

Lung cancer

Prostate cancer

Colorectal cancer

Brain tumor

Others

By End User

Hospitals

Pharmaceutical companies

Research Institutes

Others

By Region-

North America-

The US

Canada

Mexico

Europe-

Germany

The UK

France

Italy

Spain

Rest of Europe

Asia-Pacific-

China

Japan

India

South Korea

Southeast Asia

Rest of Asia Pacific

Latin America-

Brazil

Argentina

Rest of Latin America

 Middle East & Africa-

GCC Countries

South Africa

Rest of Middle East and Africa

Empower Your Decision-Making with 180 Pages Full Report @ https://www.insightaceanalytic.com/buy-report/2529

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.